

DSCR8 Antibody (C-term) Blocking Peptide
Synthetic peptide
Catalog # BP6322g**Specification****DSCR8 Antibody (C-term) Blocking Peptide -
Product Information**Primary Accession [Q96T75](#)**DSCR8 Antibody (C-term) Blocking Peptide -
Additional Information****Other Names**

Down syndrome critical region protein 8,
Cancer/testis antigen 25, CT25, Malignant
melanoma-associated protein 1, MMA-1,
Protein MTAG2, DSCR8, C21orf65, MTAG2

Target/Specificity

The synthetic peptide sequence used to
generate the antibody [AP6322g](/product/products/AP6322g) was
selected from the C-term region of human
DSCR8. A 10 to 100 fold molar excess to
antibody is recommended. Precise
conditions should be optimized for a
particular assay.

Format

Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.

Storage

Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.

Precautions

This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.

**DSCR8 Antibody (C-term) Blocking Peptide -
Protein Information**Name DSCR8 ([HGNC:16707](#))**Tissue Location****DSCR8 Antibody (C-term) Blocking Peptide
- Background**

Down syndrome, which is the most common
birth defect, is caused by trisomy 21. Studies
of patients with partial trisomy 21 have defined
a 1.6-Mb region between the DNA marker LA68
and ERG in 21q22.2 as the Down syndrome
critical region (DSCR). DSCR8 is expressed in
numerous tissues, but is not found in breast,
heart, small intestine and liver.

**DSCR8 Antibody (C-term) Blocking Peptide
- References**

Toyoda, A., et al., Genome Res.
12(9):1323-1332 (2002).Reymond, A., et al.,
Genomics 79(6):824-832 (2002).de Wit, N.J., et
al., Int. J. Cancer 98(4):547-553
(2002).Dahmane, N., et al., Genomics
48(1):12-23 (1998).

Expressed in numerous tissues; not found in breast, heart, small intestine and liver (PubMed:12036297). Isoform 1: Predominantly expressed in the testis (PubMed:11920614, PubMed:15472897). Isoform 3: Predominantly expressed in the testis, at lower level in the placenta, during malignant progression of melanocytic tumors and in several tumors of varying origins (PubMed:11920614, PubMed:15472897). Isoform 4: Predominantly expressed in the testis, at lower level in the placenta, during malignant progression of melanocytic tumors and in several tumors of varying origins (PubMed:11920614, PubMed:15472897). Isoform 5: Predominantly expressed in the testis (PubMed:11920614, PubMed:15472897). Isoform 6: Predominantly expressed in the testis (PubMed:11920614, PubMed:15472897).

DSCR8 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)